ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Researchers have uncovered new genetic rules that determine how CD8 killer T cells choose between becoming long-lasting, protective defenders or slipping into exhausted, dysfunctional states.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection.

January 30, 2026

Vol.52 No.04

Clinical Roundup

UTSW researchers boost the power of CAR T cells to fight cancer

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving their therapeutic effectiveness. The study suggests new strategies for improving the efficacy of these immune cells, known as chimeric antigen receptor T cells.

January 30, 2026

Vol.52 No.04

Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer.

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.

January 23, 2026

Vol.52 No.03

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

UTSW researchers boost the power of CAR T cells to fight cancer

Blood Cancer United: A new name at the right moment

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login